| 1 |
Buisson A, Nachury M, Guilmoteau T, Altwegg R, Treton X, Fumery M, Serrero M, Leclerc E, Caillo L, Pereira B, Amiot A, Bouguen G. Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent. Aliment Pharmacol Ther 2023;57:676-88. [PMID: 36401585 DOI: 10.1111/apt.17305] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 2 |
Ma C, Panaccione R, Xiao Y, Khandelwal Y, Murthy SK, Wong ECL, Narula N, Tsai C, Peerani F, Reise-Filteau M, Bressler B, Starkey SY, Loomes D, Sedano R, Jairath V, Bessissow T; Canadian IBD Research Consortium. REMIT-UC: Real-World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis: A Canadian IBD Research Consortium Multicenter National Cohort Study. Am J Gastroenterol 2023. [PMID: 36580497 DOI: 10.14309/ajg.0000000000002129] [Reference Citation Analysis]
|
| 3 |
Shin SH, Oh K, Hong SN, Lee J, Oh SJ, Kim ES, Na SY, Kang SB, Koh SJ, Bang KB, Jung SA, Jung SH, Kim KO, Park SH, Yang SK, Choi CH, Ye BD. Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study. Therap Adv Gastroenterol 2023;16:17562848231154103. [PMID: 36950251 DOI: 10.1177/17562848231154103] [Reference Citation Analysis]
|
| 4 |
Straatmijer T, van Schaik FDM, Bodelier AGL, Visschedijk M, de Vries AC, Ponsioen CY, Pierik M, van Bodegraven AA, West RL, de Boer NKH, Srivastava N, Romkens TEH, Hoekstra J, Oldenburg B, Dijkstra G, van der Woude JC, Löwenberg M, Mujagic Z, Biemans VBC, van der Meulen-de Jong AE, Duijvestein M. Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC Registry. Aliment Pharmacol Ther 2023;57:117-26. [PMID: 36282200 DOI: 10.1111/apt.17248] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 5 |
Laharie D, Riviere P. Editorial: selecting therapy for ulcerative colitis-think a step ahead. Aliment Pharmacol Ther 2023;57:161-2. [PMID: 36480726 DOI: 10.1111/apt.17262] [Reference Citation Analysis]
|
| 6 |
Chaparro M, Acosta D, Rodríguez C, Mesonero F, Vicuña M, Acosta MB, Fernández-Clotet A, Martínez ÁH, Arroyo M, Vera I, Ruiz-Cerulla A, Sicilia B, Cabello Tapia MJ, Villafranca CM, Castro-Poceiro J, Cadilla JM, Sierra-Ausín M, Vázquez Morón JM, Lidón RV, Bermejo F, Royo V, Calafat M, González-Muñoza C, Carnerero EL, Marcos NM, Torrealba L, Alonso-Galán H, Benítez JM, Nieto YB, Diz-Lois Palomares MT, García MJ, Muñoz JF, Armesto González EM, Calvet X, Hernández-Camba A, Madrigal Domínguez RE, Menchén L, Pérez Calle JL, Piqueras M, Sadornil CD, Botella B, de Jesús Martínez-Pérez T, Ramos L, Rodríguez-Grau MC, San Miguel E, Fernández Forcelledo JL, Fradejas Salazar PM, García-Sepulcre M, Gutiérrez A, Llaó J, Abizanda ES, Boscá-Watts M, Iyo E, Keco-Huerga A, Bonil CM, González EP, Pérez-Galindo P, Varela P, Gisbert JP. Real-world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness and safety. Am J Gastroenterol 2022. [PMID: 36716287 DOI: 10.14309/ajg.0000000000002145] [Reference Citation Analysis]
|
| 7 |
Wang M, Li J, Yin Y, Liu L, Wang Y, Qu Y, Hong Y, Ji S, Zhang T, Wang N, Liu J, Cao X, Zao X, Zhang S. Network pharmacology and in vivo experiment-based strategy to investigate mechanisms of JingFangFuZiLiZhong formula for ulcerative colitis. Ann Med 2022;54:3219-33. [PMID: 36382627 DOI: 10.1080/07853890.2022.2095665] [Reference Citation Analysis]
|
| 8 |
Taneja V, El-Dallal M, Haq Z, Tripathi K, Systrom HK, Wang LF, Said H, Bain PA, Zhou Y, Feuerstein JD. Effectiveness and Safety of Tofacitinib for Ulcerative Colitis: Systematic Review and Meta-analysis. J Clin Gastroenterol 2022;56:e323-33. [PMID: 34516458 DOI: 10.1097/MCG.0000000000001608] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 9 |
Flood P, Fanning A, Woznicki JA, Crowley T, Christopher A, Vaccaro A, Houston A, McSweeney S, Ross S, Hogan A, Brint E, Skowyra A, Bustamante M, Ambrose M, Moloney G, MacSharry J, Hammarström ML, Hurley M, Fitzgibbons C, Quigley EMM, Shanahan F, Zulquernain SA, McCarthy J, Dodson GS, Dabbagh K, McRae BL, Melgar S, Nally K. DNA sensor-associated type I interferon signaling is increased in ulcerative colitis and induces JAK-dependent inflammatory cell death in colonic organoids. Am J Physiol Gastrointest Liver Physiol 2022;323:G439-60. [PMID: 36165492 DOI: 10.1152/ajpgi.00104.2022] [Reference Citation Analysis]
|
| 10 |
Matsuoka K, Hisamatsu T, Kim HJ, Ye BD, Arai S, Hoshi M, Yuasa H, Tabira J, Toyoizumi S, Shi N, Woo JS, Hibi T. Safety and efficacy of long-term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open. J Gastroenterol Hepatol 2022;37:1884-92. [PMID: 35734858 DOI: 10.1111/jgh.15923] [Reference Citation Analysis]
|
| 11 |
Mishra S, Jena A, Kakadiya R, Sharma V, Ahuja V. Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective. Expert Rev Gastroenterol Hepatol 2022;16:737-52. [PMID: 35875997 DOI: 10.1080/17474124.2022.2106216] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 12 |
Verstockt B, Volk V, Jaeckel C, Alsoud D, Sabino J, Nikolaus S, Outtier A, Krönke N, Feuerhake F, De Hertogh G, Rosenstiel P, Vermeire S, Schreiber S, Ferrante M, Aden K. Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis. Aliment Pharmacol Ther 2022;56:282-91. [PMID: 35484689 DOI: 10.1111/apt.16955] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 13 |
Long MD, Afzali A, Fischer M, Hudesman D, Abdalla M, McCabe R, Cohen BL, Ungaro RC, Harlan W, Hanson J, Konijeti G, Polyak S, Ritter T, Salzberg B, Seminerio J, English E, Zhang X, Sharma PP, Herfarth HH. Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting. Inflamm Bowel Dis 2022:izac121. [PMID: 35700276 DOI: 10.1093/ibd/izac121] [Reference Citation Analysis]
|
| 14 |
Panaccione R, Abreu MT, Lazariciu I, Mundayat R, Lawendy N, Salese L, Woolcott JC, Sands BE, Chaparro M. Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open-label, long-term extension study, OCTAVE open. Aliment Pharmacol Ther 2022;55:1534-44. [PMID: 35246988 DOI: 10.1111/apt.16848] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 15 |
Sleutjes JAM, Roeters van Lennep JE, van der Woude CJ, de Vries AC. Lipid Changes After Induction Therapy in Patients with Inflammatory Bowel Disease: Effect of Different Drug Classes and Inflammation. Inflamm Bowel Dis 2022:izac100. [PMID: 35590447 DOI: 10.1093/ibd/izac100] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 16 |
Wang W, Pekow J. Editorial: response to tofacitinib is associated with high rates of long-term treatment persistence. Aliment Pharmacol Ther 2022;55:1222-3. [PMID: 35429025 DOI: 10.1111/apt.16891] [Reference Citation Analysis]
|
| 17 |
Sagami S, Kobayashi T, Aihara K, Umeda M, Odajima K, Morikubo H, Asonuma K, Miyatani Y, Fukuda T, Matsubayashi M, Kiyohara H, Nakano M, Hibi T. Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis. Aliment Pharmacol Ther 2022;55:1320-9. [PMID: 35218038 DOI: 10.1111/apt.16817] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 18 |
Chiorean MV, Allegretti JR, Sharma PP, Chastek B, Salese L, Bell EJ, Peterson-brandt J, Cappelleri JC, Guo X, Khan N. Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02215-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 19 |
Wang Y, Wan Z, Jin R, Xu T, Ouyang Y, Wang B, Ruan G, Bai X. Tofacitinib for extraintestinal manifestations of inflammatory bowel disease: A literature review. International Immunopharmacology 2022;105:108517. [DOI: 10.1016/j.intimp.2022.108517] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 20 |
Hyun HK, Zhang H, Yu J, Kang EA, Park J, Park SJ, Park JJ, Kim TI, Kim WH, Cheon JH. Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02225-w] [Reference Citation Analysis]
|
| 21 |
Macaluso FS, Maida M, Ventimiglia M, Orlando A. Effectiveness and safety of tofacitinib for the treatment of ulcerative colitis: A single-arm meta-analysis of observational studies. Dig Liver Dis 2022;54:183-91. [PMID: 34011482 DOI: 10.1016/j.dld.2021.04.018] [Reference Citation Analysis]
|
| 22 |
Katsanos KH, Armuzzi A. Effectiveness and safety of tofacitinib in ulcerative colitis: Done is better than perfect. Dig Liver Dis 2022;54:151-3. [PMID: 34953762 DOI: 10.1016/j.dld.2021.11.017] [Reference Citation Analysis]
|
| 23 |
Sandborn WJ, Lawendy N, Danese S, Su C, Loftus EV Jr, Hart A, Dotan I, Damião AOMC, Judd DT, Guo X, Modesto I, Wang W, Panés J. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment. Aliment Pharmacol Ther 2022;55:464-78. [PMID: 34854095 DOI: 10.1111/apt.16712] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 24.0] [Reference Citation Analysis]
|
| 24 |
Taxonera C, Olivares D, Alba C. Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis. Inflamm Bowel Dis 2022;28:32-40. [PMID: 33586766 DOI: 10.1093/ibd/izab011] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 22.0] [Reference Citation Analysis]
|
| 25 |
Ishida N, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Real-World Efficacy and Safety Monitoring for Predicting Continuation of Tofacitinib Therapy in Patients with Ulcerative Colitis. Dig Dis Sci 2022;67:3984-92. [PMID: 34460029 DOI: 10.1007/s10620-021-07233-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 26 |
Taxonera C, Carpio López D, Cabez Manas A, Hinojosa del Val JE. Clinical settings with tofacitinib in ulcerative colitis. Rev Esp Enferm Dig 2022. [DOI: 10.17235/reed.2022.8660/2022] [Reference Citation Analysis]
|
| 27 |
Lucaciu LA, Constantine-Cooke N, Plevris N, Siakavellas S, Derikx LAAP, Jones GR, Lees CW. Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis. Therap Adv Gastroenterol 2021;14:17562848211064004. [PMID: 34987608 DOI: 10.1177/17562848211064004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 28 |
Garrido I, Lopes S, Macedo G. Hit the Road JAK! The Role of New Oral Treatment in Inflammatory Bowel Disease. Inflamm Bowel Dis 2021;27:2010-22. [PMID: 33742651 DOI: 10.1093/ibd/izab037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 29 |
Kim JW, Kim SY. The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment. Int J Mol Sci 2021;22:11322. [PMID: 34768752 DOI: 10.3390/ijms222111322] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 30 |
Sleutjes JAM, Roeters van Lennep JE, Boersma E, Menchen LA, Laudes M, Farkas K, Molnár T, Kennedy NA, Pierik MJ, van der Woude CJ, de Vries AC. Systematic review with meta-analysis: effect of inflammatory bowel disease therapy on lipid levels. Aliment Pharmacol Ther 2021;54:999-1012. [PMID: 34453860 DOI: 10.1111/apt.16580] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 31 |
Straatmijer T, van Gennep S, Duijvestein M, Ponsioen CIJ, Gecse KB, D'Haens GR, Löwenberg M. Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis. Eur J Gastroenterol Hepatol 2021;33:1288-97. [PMID: 33405424 DOI: 10.1097/MEG.0000000000002028] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 32 |
Lo SW, Connell W, Kamm MA, Lust M, Wright EK. Letter: tofacitinib in biologic-experienced ulcerative colitis-a single-centre real-world experience in Australia. Aliment Pharmacol Ther 2021;54:532-3. [PMID: 34331806 DOI: 10.1111/apt.16468] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 33 |
Biemans VBC, Straatmijer T, Hoentjen F, Pierik MJ. Letter: tofacitinib in treatment-refractory ulcerative colitis-a single centre real-world experience in Australia. Authors' reply. Aliment Pharmacol Ther 2021;54:534-5. [PMID: 34331810 DOI: 10.1111/apt.16505] [Reference Citation Analysis]
|
| 34 |
Sleutjes JAM, van Lennep JER, van der Woude CJ, de Vries AC. Thromboembolic and atherosclerotic cardiovascular events in inflammatory bowel disease: epidemiology, pathogenesis and clinical management. Therap Adv Gastroenterol 2021;14:17562848211032126. [PMID: 34377149 DOI: 10.1177/17562848211032126] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 35 |
Li Y, Jia Y, Cui T, Zhang J. IL-6/STAT3 signaling pathway regulates the proliferation and damage of intestinal epithelial cells in patients with ulcerative colitis via H3K27ac. Exp Ther Med 2021;22:890. [PMID: 34194568 DOI: 10.3892/etm.2021.10322] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 36 |
Mahmoud R, van Lieshout C, Frederix GWJ, Jharap B, Oldenburg B. Continuation of Anti-TNF in Patients With Ulcerative Colitis in Remission Is Not Cost-effective Compared With Treatment Withdrawal: A Markov Model. J Crohns Colitis 2021;15:709-18. [PMID: 33125060 DOI: 10.1093/ecco-jcc/jjaa219] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 37 |
Lucaciu L, Constantine-cooke N, Plevris N, Siakavellas S, Derikx L, Jones G, Lees C. Real-world experience with tofacitinib in ulcerative colitis - a systematic review and meta-analysis.. [DOI: 10.1101/2021.04.27.21256170] [Reference Citation Analysis]
|
| 38 |
Arzi RS, Kay A, Raychman Y, Sosnik A. Excipient-Free Pure Drug Nanoparticles Fabricated by Microfluidic Hydrodynamic Focusing. Pharmaceutics 2021;13:529. [PMID: 33920184 DOI: 10.3390/pharmaceutics13040529] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 39 |
Jodeleit H, Winkelmann P, Caesar J, Sterz S, Holdt LM, Beigel F, Stallhofer J, Breiteneicher S, Bartnik E, Leeuw T, Siebeck M, Gropp R. Head-to-head study of oxelumab and adalimumab in a mouse model of ulcerative colitis based on NOD/Scid IL2Rγnull mice reconstituted with human peripheral blood mononuclear cells. Dis Model Mech 2021;14:dmm046995. [PMID: 33293281 DOI: 10.1242/dmm.046995] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 40 |
Dwadasi S, Zafer M, Goens D, Paknikar R, Dalal S, Cohen RD, Pekow J, Rubin DT, Sakuraba A, Micic D. Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis. Inflamm Bowel Dis 2021;27:1620-5. [PMID: 33319248 DOI: 10.1093/ibd/izaa326] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 41 |
Heo Y. Tofacitinib in ulcerative colitis: a profile of its use. Drugs Ther Perspect 2020;36:553-563. [DOI: 10.1007/s40267-020-00789-9] [Reference Citation Analysis]
|
| 42 |
Hoffmann P, Globig AM, Thomann AK, Grigorian M, Krisam J, Hasselblatt P, Reindl W, Gauss A. Tofacitinib in Treatment-Refractory Moderate to Severe Ulcerative Colitis: Real-World Experience from a Retrospective Multicenter Observational Study. J Clin Med 2020;9:E2177. [PMID: 32664204 DOI: 10.3390/jcm9072177] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 43 |
Biemans VB, Verstockt B. Tofacitinib, two-faced Janus in ulcerative colitis and Crohn's disease? United European Gastroenterol J 2020;8:753-4. [PMID: 32640933 DOI: 10.1177/2050640620942641] [Reference Citation Analysis]
|
| 44 |
Magro F, Estevinho MM. Is tofacitinib a game-changing drug for ulcerative colitis? United European Gastroenterol J 2020;8:755-63. [PMID: 32552501 DOI: 10.1177/2050640620935732] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 45 |
Biemans VBC, Sleutjes JAM, de Vries AC, Bodelier AGL, Dijkstra G, Oldenburg B, Löwenberg M, van Bodegraven AA, van der Meulen-de Jong AE, de Boer NKH, Srivastava N, West RL, Römkens TEH, Horjus Talabur Horje CS, Jansen JM, van der Woude CJ, Hoekstra J, Weersma RK, van Schaik FDM, Hoentjen F, Pierik MJ; Dutch Initiative on Crohn and Colitis (ICC). Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry. Aliment Pharmacol Ther 2020;51:880-8. [PMID: 32237087 DOI: 10.1111/apt.15689] [Cited by in Crossref: 45] [Cited by in F6Publishing: 25] [Article Influence: 15.0] [Reference Citation Analysis]
|
